ResMed - RMD Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

8 brokerages have issued 1 year price targets for ResMed's shares. Their RMD share price forecasts range from $245.00 to $280.00. On average, they anticipate the company's stock price to reach $263.17 in the next year. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

ResMed's stock was trading at $208.13 at the beginning of 2023. Since then, RMD shares have increased by 3.7% and is now trading at $215.82.
View the best growth stocks for 2023 here.

ResMed saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,300,000 shares, an increase of 20.4% from the February 28th total of 1,080,000 shares. Based on an average daily volume of 653,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.9% of the company's stock are sold short.
View ResMed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our RMD earnings forecast.

ResMed Inc. (NYSE:RMD) issued its earnings results on Thursday, January, 26th. The medical equipment provider reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.04. The medical equipment provider had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $996.22 million. ResMed had a trailing twelve-month return on equity of 25.46% and a net margin of 21.51%. The company's revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.47 earnings per share.
Read the conference call transcript.

ResMed announced a quarterly dividend on Thursday, January 26th. Shareholders of record on Thursday, February 9th will be given a dividend of $0.44 per share on Thursday, March 16th. This represents a $1.76 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date is Wednesday, February 8th.
Read our dividend analysis for RMD.

ETFs with the largest weight of ResMed (NYSE:RMD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Motley Fool Mid-Cap Growth ETF (TMFM), Fidelity Digital Health ETF (FDHT), Simplify Health Care ETF (PINK), Emerge EMPWR Sustainable Select Growth Equity ETF (EMGC), iShares U.S. Medical Devices ETF (IHI), BlackRock Future Health ETF (BMED) and Capital Group Global Growth Equity ETF (CGGO).

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.83%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include WCM Investment Management LLC (2.61%), Geode Capital Management LLC (2.13%), Ownership Capital B.V. (0.96%), JPMorgan Chase & Co. (0.90%), Norges Bank (0.80%) and Legal & General Group Plc (0.72%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMD stock can currently be purchased for approximately $215.82.

ResMed (NYSE:RMD) has a market capitalization of $31.71 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.51 on an earnings per share basis.

The company employs 8,160 workers across the globe.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.